{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:35:54Z","timestamp":1761766554888},"reference-count":23,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2019.1875","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T10:39:03Z","timestamp":1560163143000},"source":"Crossref","is-referenced-by-count":5,"title":["Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)\u2011positive advanced salivary duct carcinoma: A case report"],"prefix":"10.3892","author":[{"given":"Takahiko","family":"Gibo","sequence":"first","affiliation":[{"name":"Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nodoka","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Gomi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshirou","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takesumi","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin\u2011Ichi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonobu","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390\u20118621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"key20200713202443_b1-mco-0-0-1875","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.5858\/133.11.1763","article-title":"Update on selected salivary gland neoplasms","volume":"133","author":"McHugh","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"key20200713202443_b2-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1245\/s10434-015-5082-2","article-title":"Clinical outcomes and prognostic factors for salivary duct carcinoma: A multi-institutional analysis of 141 patients","volume":"23","author":"Otsuka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"key20200713202443_b3-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0030-4220(94)90119-8","article-title":"Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature","volume":"78","author":"Barnes","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"key20200713202443_b4-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"E820","DOI":"10.1002\/hed.24107","article-title":"Salivary duct carcinoma: Treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck"},{"key":"key20200713202443_b5-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.oraloncology.2012.05.004","article-title":"Systemic therapy in the management of metastatic or advanced salivary gland cancers","volume":"48","author":"Lagha","year":"2012","journal-title":"Oral Oncol"},{"key":"key20200713202443_b6-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","article-title":"Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma","volume":"20","author":"Masubuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"key20200713202443_b7-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archotol.133.10.1031","article-title":"Amplification and overexpression of HER2\/neu gene and HER2\/neu protein in salivary duct carcinoma of the parotid gland","volume":"133","author":"Cornolti","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"key20200713202443_b8-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2559.2004.01781.x","article-title":"Expression of HER-2\/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry","volume":"44","author":"Dagrada","year":"2004","journal-title":"Histopathology"},{"key":"key20200713202443_b9-mco-0-0-1875","first-page":"ZE04","article-title":"Human epidermal growth factor receptor 2 (HER2\/neu) in salivary gland carcinomas: A review of literature","volume":"9","author":"Alotaibi","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"key20200713202443_b10-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"key20200713202443_b11-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1078\/0344-0338-00136","article-title":"Salivary duct carcinoma-A highly aggressive salivary gland tumor with HER-2\/neu oncoprotein overexpression","volume":"197","author":"Sk\u00e1lov\u00e1","year":"2001","journal-title":"Pathol Res Pract"},{"key":"key20200713202443_b12-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: A series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin Belg"},{"key":"key20200713202443_b13-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.oooo.2016.03.020","article-title":"Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab","volume":"122","author":"Ghazali","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"key20200713202443_b14-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000355219","article-title":"Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma","volume":"6","author":"Kadowaki","year":"2013","journal-title":"Case Rep Oncol"},{"key":"key20200713202443_b15-mco-0-0-1875","first-page":"16251634","article-title":"Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"key20200713202443_b16-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"key20200713202443_b17-mco-0-0-1875","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncol"},{"key":"key20200713202443_b18-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/hed.24634","article-title":"Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature","volume":"39","author":"Thorpe","year":"2017","journal-title":"Head Neck"},{"key":"key20200713202443_b19-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-line treatment of HER2-positive salivary gland tumor: Ado-Trastuzumab emtansine (T-DM1) after progression on trastuzumab","volume":"11","author":"Corr\u00eaa","year":"2018","journal-title":"Case Rep Oncol"},{"key":"key20200713202443_b20-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"key20200713202443_b21-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3950\/jibiinkoka.117.1108","article-title":"A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy","volume":"117","author":"Iguchi","year":"2014","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"key":"key20200713202443_b22-mco-0-0-1875","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.5858\/2008-132-1635-COQIWC","article-title":"Comparison of quantitative immunofluorescence with conventional methods for HER2\/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer","volume":"132","author":"Giltnane","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"key20200713202443_b23-mco-0-0-1875","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T03:56:41Z","timestamp":1663646201000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2019.1875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.3892\/mco.2019.1875","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]}}}